We conducted a retrospective, multicenter study evaluating the safety of discontinuing maintenance therapy for cryptococcal meningitis after immune reconstitution. Inclusion criteria were a previous definitive diagnosis of cryptococcal meningitis, a CD4 cell count of >100 cells/muL while receiving highly active antiretroviral therapy (HAART), and the subsequent discontinuation of maintenance therapy for cryptococcal meningitis. The primary end point was relapse of cryptococcal disease. As of July 2002, 100 patients were enrolled. When maintenance therapy was discontinued, the median CD4 cell count was 259 cells/muL and the median plasma virus load was <2.30 log(10) copies/mL, and serum cryptococcal antigen was undetectable in 56 patients. During a median follow-up period of 28.4 months (range, 6.7-64.5; 262 person-years), 4 events were observed (incidence, 1.53 events per 100 person-years; 95% confidence interval, 0.42-3.92). Three of these patients had a CD4 cell count of >100 cells/mL and a positive serum cryptococcal antigen test result during the recurrent episode. In conclusion, discontinuation of maintenance therapy for cryptococcal meningitis is safe if the CD4 cell count increases to >100 cells/mL while receiving HAART. Recurrent cryptococcal infection should be suspected in patients whose serum cryptococcal antigen test results revert back to positive after discontinuation of maintenance therapy.

Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: An international observational study / Mussini, Cristina; P., Pezzotti; J., MIRO' MEDA; JC LOPEZ BERNALDO DE, Quiros; E., Martinez; P., Cinque; V., Borghi; Bedini, Andrea; P., Domingo; P., Cahn; P., Bossi; A., DE LUCA; A., D'ARMINIO MONFORTE; M., Nelson; N., Nwokolo; S., Helou; R., Neuroni; G., Jacchetti; S., Antinori; A., Lazzarin; Cossarizza, Andrea; Esposito, Roberto; A., Antinori; Ja, Aberg. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - STAMPA. - 38:(2004), pp. 565-571. [10.1086/381261]

Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: An international observational study

MUSSINI, Cristina;BEDINI, Andrea;COSSARIZZA, Andrea;ESPOSITO, Roberto;
2004

Abstract

We conducted a retrospective, multicenter study evaluating the safety of discontinuing maintenance therapy for cryptococcal meningitis after immune reconstitution. Inclusion criteria were a previous definitive diagnosis of cryptococcal meningitis, a CD4 cell count of >100 cells/muL while receiving highly active antiretroviral therapy (HAART), and the subsequent discontinuation of maintenance therapy for cryptococcal meningitis. The primary end point was relapse of cryptococcal disease. As of July 2002, 100 patients were enrolled. When maintenance therapy was discontinued, the median CD4 cell count was 259 cells/muL and the median plasma virus load was <2.30 log(10) copies/mL, and serum cryptococcal antigen was undetectable in 56 patients. During a median follow-up period of 28.4 months (range, 6.7-64.5; 262 person-years), 4 events were observed (incidence, 1.53 events per 100 person-years; 95% confidence interval, 0.42-3.92). Three of these patients had a CD4 cell count of >100 cells/mL and a positive serum cryptococcal antigen test result during the recurrent episode. In conclusion, discontinuation of maintenance therapy for cryptococcal meningitis is safe if the CD4 cell count increases to >100 cells/mL while receiving HAART. Recurrent cryptococcal infection should be suspected in patients whose serum cryptococcal antigen test results revert back to positive after discontinuation of maintenance therapy.
38
565
571
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: An international observational study / Mussini, Cristina; P., Pezzotti; J., MIRO' MEDA; JC LOPEZ BERNALDO DE, Quiros; E., Martinez; P., Cinque; V., Borghi; Bedini, Andrea; P., Domingo; P., Cahn; P., Bossi; A., DE LUCA; A., D'ARMINIO MONFORTE; M., Nelson; N., Nwokolo; S., Helou; R., Neuroni; G., Jacchetti; S., Antinori; A., Lazzarin; Cossarizza, Andrea; Esposito, Roberto; A., Antinori; Ja, Aberg. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - STAMPA. - 38:(2004), pp. 565-571. [10.1086/381261]
Mussini, Cristina; P., Pezzotti; J., MIRO' MEDA; JC LOPEZ BERNALDO DE, Quiros; E., Martinez; P., Cinque; V., Borghi; Bedini, Andrea; P., Domingo; P., Cahn; P., Bossi; A., DE LUCA; A., D'ARMINIO MONFORTE; M., Nelson; N., Nwokolo; S., Helou; R., Neuroni; G., Jacchetti; S., Antinori; A., Lazzarin; Cossarizza, Andrea; Esposito, Roberto; A., Antinori; Ja, Aberg
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/612578
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 105
  • ???jsp.display-item.citation.isi??? 77
social impact